SOD3 and cancer: Although methylation changes are observed even in precancerous stages with chronic inflammation, the current data suggest the most prominent role for methylation-mediated SOD3 silencing in the presence of high RAS activity in advanced well-differentiated and poorly differentiated aggressive cancers.